However, the molecular subgroup in which DNMT3A mutations are found significantly associated to a worse outcome varies across studies, most reports showing that the poor prognostic impact of DNMT3A mutations was most obvious in CN-AML with NPM1/FLT3 non-favorable genotypes [11, 23–26]. This evidence concerns the gene NPM1 and acute myeloid leukemia.